
## Pieter Evenepoel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2776557/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal of Medicine, 2004, 350, 1516-1525.	27.0	1,023
2	Executive summary of the 2017 KDIGO Chronic KidneyÂDisease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney International, 2017, 92, 26-36.	5.2	698
3	Uremic toxins originating from colonic microbial metabolism. Kidney International, 2009, 76, S12-S19.	5.2	349
4	Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney International, 2006, 69, 1081-1087.	5.2	340
5	Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International, 2008, 73, 1174-1180.	5.2	276
6	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology Dialysis Transplantation, 2004, 19, 1281-1287.	0.7	273
7	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. American Journal of Kidney Diseases, 2016, 67, 483-498.	1.9	271
8	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1182-1189.	4.5	265
9	p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrology Dialysis Transplantation, 2010, 25, 219-224.	0.7	260
10	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Annals of Internal Medicine, 2018, 168, 422.	3.9	228
11	The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage. American Journal of Kidney Diseases, 2009, 54, 891-901.	1.9	219
12	Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney International, 2004, 65, 1842-1849.	5.2	206
13	The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrology Dialysis Transplantation, 2011, 26, 759-761.	0.7	203
14	Influence of dietary protein supplements on the formation of bacterial metabolites in the colon Gut, 1997, 41, 70-76.	12.1	200
15	The gut–kidney axis. Pediatric Nephrology, 2017, 32, 2005-2014.	1.7	188
16	Intrarenal Resistive Index after Renal Transplantation. New England Journal of Medicine, 2013, 369, 1797-1806.	27.0	185
17	Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney International, 2003, 64, 2238-2243.	5.2	178
18	Gas Chromatographic–Mass Spectrometric Analysis for Measurement of p-Cresol and Its Conjugated Metabolites in Uremic and Normal Serum, Clinical Chemistry, 2005, 51, 1535-1538	3.2	172

#	Article	IF	CITATIONS
19	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics, 2004, 75, 434-447.	4.7	157
20	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 1997-2004.	4.7	157
21	Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. American Journal of Kidney Diseases, 2004, 44, 278-285.	1.9	155
22	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3479-3487.	6.1	144
23	Tertiary â€~Hyperphosphatoninism' Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 1193-1200.	4.7	143
24	Sclerostin: Another Vascular Calcification Inhibitor?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3221-3228.	3.6	143
25	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation, 2003, 75, 665-672.	1.0	142
26	p-Cresyl Sulfate and Indoxyl Sulfate in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1932-1938.	4.5	142
27	Intestinal microbiome and fitness in kidney disease. Nature Reviews Nephrology, 2019, 15, 531-545.	9.6	140
28	Influenza Vaccination Is Efficacious and Safe in Renal Transplant Recipients. American Journal of Transplantation, 2008, 8, 332-337.	4.7	139
29	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. Transplantation, 2001, 72, 1655-1661.	1.0	128
30	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nature Reviews Nephrology, 2021, 17, 153-171.	9.6	126
31	Recovery of Hyperphosphatoninism and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1829-1836.	4.5	124
32	The Histology of Kidney Transplant Failure. Transplantation, 2014, 98, 427-435.	1.0	124
33	Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrology Dialysis Transplantation, 2005, 20, 1714-1720.	0.7	123
34	Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney International, 2016, 90, 1184-1190.	5.2	123
35	Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. Journal of the American Society of Nephrology: JASN, 2019, 30, 751-766.	6.1	122
36	Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney International, 2015, 88, 235-240.	5.2	118

#	Article	IF	CITATIONS
37	Digestibility of Cooked and Raw Egg Protein in Humans as Assessed by Stable Isotope Techniques. Journal of Nutrition, 1998, 128, 1716-1722.	2.9	116
38	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrology Dialysis Transplantation, 2015, 30, 288-293.	0.7	111
39	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney International, 2005, 67, 2477-2487.	5.2	108
40	Evidence for impaired assimilation of protein in chronic renal failure. Kidney International, 2003, 64, 2196-2203.	5.2	107
41	European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrology Dialysis Transplantation, 2021, 36, 42-59.	0.7	107
42	Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial. British Journal of Nutrition, 2012, 108, 2229-2242.	2.3	106
43	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney International, 2014, 85, 636-640.	5.2	106
44	The Influence of CKD on Colonic Microbial Metabolism. Journal of the American Society of Nephrology: JASN, 2016, 27, 1389-1399.	6.1	106
45	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. Artificial Organs, 2006, 30, 276-284.	1.9	105
46	Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. Nephrology Dialysis Transplantation, 2013, 28, 3024-3030.	0.7	105
47	Albumin is the main plasma binding protein for indoxyl sulfate and <i>p</i> â€cresyl sulfate. Biopharmaceutics and Drug Disposition, 2013, 34, 165-175.	1.9	104
48	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. Clinical Pharmacokinetics, 2004, 43, 741-762.	3.5	102
49	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes and Endocrinology,the, 2018, 6, 319-331.	11.4	102
50	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. Journal of Clinical Pharmacology, 2003, 43, 866-880.	2.0	99
51	A Review of Albumin Binding in CKD. American Journal of Kidney Diseases, 2008, 51, 839-850.	1.9	99
52	Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrology Dialysis Transplantation, 2007, 22, 1730-1737.	0.7	96
53	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1268-1276.	4.5	96
54	Superior dialytic clearance of β2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney International, 2006, 70, 794-799.	5.2	93

#	Article	IF	CITATIONS
55	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1508-1514.	4.5	93
56	Renal safety in patients treated with bisphosphonates for osteoporosis: A review. Journal of Bone and Mineral Research, 2013, 28, 2049-2059.	2.8	91
57	Gastric emptying in hyperemesis gravidarum and non-dyspeptic pregnancy. Alimentary Pharmacology and Therapeutics, 1999, 13, 237-243.	3.7	88
58	Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrology Dialysis Transplantation, 2011, 26, 1464-1467.	0.7	86
59	Amount and fate of egg protein escaping assimilation in the small intestine of humans. American Journal of Physiology - Renal Physiology, 1999, 277, G935-G943.	3.4	85
60	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrology Dialysis Transplantation, 2004, 19, 1895-1901.	0.7	83
61	Detoxifying Capacity and Kinetics of Prometheus <sup>®</sup> – A New Extracorporeal System for the Treatment of Liver Failure. Blood Purification, 2005, 23, 349-358.	1.8	82
62	Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients. Seminars in Nephrology, 2013, 33, 191-203.	1.6	81
63	Intestinal Barrier Function in Chronic Kidney Disease. Toxins, 2018, 10, 298.	3.4	78
64	Time Profiles of Peritoneal and Renal Clearances of Different Uremic Solutes in Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2005, 46, 512-519.	1.9	77
65	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrology Dialysis Transplantation, 2010, 25, 2672-2679.	0.7	77
66	A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism. American Journal of Transplantation, 2014, 14, 2545-2555.	4.7	77
67	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. PLoS ONE, 2015, 10, e0140820.	2.5	77
68	Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. Alimentary Pharmacology and Therapeutics, 1998, 12, 1011-1019.	3.7	74
69	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0153893.	2.5	74
70	Calcium Metabolism in the Early Posttransplantation Period. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 665-672.	4.5	72
71	The Colon: An Overlooked Site for Therapeutics in Dialysis Patients. Seminars in Dialysis, 2013, 26, 323-332.	1.3	71
72	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2008, 24, 278-285.	0.7	70

#	Article	IF	CITATIONS
73	Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrology Dialysis Transplantation, 2004, 19, 469-473.	0.7	69
74	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. American Journal of Kidney Diseases, 2007, 49, 642-649.	1.9	68
75	Major Coagulation Disturbances During Fractionated Plasma Separation and Adsorption. American Journal of Transplantation, 2007, 7, 2195-2199.	4.7	65
76	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrology Dialysis Transplantation, 2008, 23, 2033-2042.	0.7	65
77	Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. Journal of Chromatography A, 2009, 1216, 4684-4688.	3.7	65
78	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. Journal of the American Society of Nephrology: JASN, 2016, 27, 281-292.	6.1	65
79	Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study. Kidney International, 2006, 70, 192-198.	5.2	63
80	Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial. American Journal of Kidney Diseases, 2009, 54, 77-85.	1.9	63
81	Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. American Journal of Clinical Nutrition, 2004, 80, 1536-1543.	4.7	62
82	Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?. Seminars in Nephrology, 2014, 34, 151-163.	1.6	62
83	Bone mineral density, bone turnover markers, andÂincident fractures in de novo kidney transplantÂrecipients. Kidney International, 2019, 95, 1461-1470.	5.2	61
84	Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. American Journal of Kidney Diseases, 2002, 39, 315-323.	1.9	60
85	Removal of the Uremic Retention Solute <i>p</i> â€Cresol Using Fractionated Plasma Separation and Adsorption. Artificial Organs, 2008, 32, 214-219.	1.9	60
86	Review article: nonâ€biological liver support in liver failure. Alimentary Pharmacology and Therapeutics, 2006, 23, 351-363.	3.7	59
87	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1525-1533.	4.5	59
88	Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant Recipients. American Journal of Transplantation, 2002, 2, 989-992.	4.7	58
89	Metabolism, Protein Binding, and Renal Clearance of Microbiota–Derived p-Cresol in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1136-1144.	4.5	57
90	Validation of the lactose-[13C]ureide breath test for determination of orocecal transit time by scintigraphy. Journal of Nuclear Medicine, 1999, 40, 1451-5.	5.0	57

#	Article	IF	CITATIONS
91	The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clinical Transplantation, 2003, 17, 234-241.	1.6	54
92	The value of tuberculin skin testing in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 433-438.	0.7	54
93	The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon. British Journal of Nutrition, 2006, 96, 1078-1086.	2.3	53
94	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
95	Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4669-4676.	3.6	53
96	Bone-Vascular Axis in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2019, 26, 472-483.	1.4	53
97	Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Scientific Reports, 2020, 10, 6586.	3.3	53
98	Acute toxic renal failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2004, 18, 37-52.	4.0	52
99	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney International, 2015, 87, 210-216.	5.2	52
100	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrology Dialysis Transplantation, 2016, 31, 1211-1219.	0.7	52
101	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. Nephron Clinical Practice, 2008, 110, c80-c85.	2.3	51
102	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transplant International, 2013, 26, 813-821.	1.6	51
103	From skeletal to cardiovascular disease in 12 steps—the evolution of sclerostin as a major player in CKD-MBD. Pediatric Nephrology, 2016, 31, 195-206.	1.7	51
104	Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. Journal of Bone and Mineral Research, 2019, 34, 262-269.	2.8	51
105	Late Referral of Patients With Chronic Kidney Disease: No Time to Waste. Mayo Clinic Proceedings, 2006, 81, 1487-1494.	3.0	50
106	C3D DEPOSITION IN PERITUBULAR CAPILLARIES INDICATES A VARIANT OF ACUTE RENAL ALLOGRAFT REJECTION CHARACTERIZED BY A WORSE CLINICAL OUTCOME. Transplantation, 2003, 76, 102-108.	1.0	47
107	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	2.7	47
108	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. American Journal of Transplantation, 2009, 9, 2470-2478.	4.7	46

#	Article	IF	CITATIONS
109	Sclerostin in chronic kidney disease–mineral bone disorder think first before you block it!. Nephrology Dialysis Transplantation, 2019, 34, 408-414.	0.7	46
110	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. Blood Purification, 2003, 21, 244-252.	1.8	44
111	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. EBioMedicine, 2016, 4, 162-169.	6.1	44
112	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. American Journal of Transplantation, 2015, 15, 2900-2907.	4.7	43
113	Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. Kidney International, 2012, 81, 227-229.	5.2	41
114	Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper. Nephrology Dialysis Transplantation, 2017, 32, 1608-1613.	0.7	41
115	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney International, 2008, 74, 265-275.	5.2	40
116	A liquid chromatography – tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. Analytica Chimica Acta, 2016, 936, 149-156.	5.4	40
117	Bone histomorphometry in de novo renal transplant recipients indicates a further decline inÂbone resorption 1 year posttransplantation. Kidney International, 2017, 91, 469-476.	5.2	40
118	Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney International, 2021, 100, 546-558.	5.2	39
119	Production of Egg Proteins, Enriched with L-Leucine-13C1, for the Study of Protein Assimilation in Humans Using the Breath Test Technique ,. Journal of Nutrition, 1997, 127, 327-331.	2.9	38
120	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrology Dialysis Transplantation, 2002, 17, 923-926.	0.7	38
121	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. Clinical Infectious Diseases, 2015, 60, 1505-1511.	5.8	38
122	Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. Pharmacological Research, 2018, 133, 101-107.	7.1	38
123	Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. Nephrology Dialysis Transplantation, 2020, 35, 1794-1801.	0.7	37
124	Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS ONE, 2017, 12, e0176411.	2.5	37
125	Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1887-1892.	4.5	36
126	Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 2017-2022.	0.7	36

#	Article	IF	CITATIONS
127	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clinical Transplantation, 2012, 26, 393-402.	1.6	36
128	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transplant International, 2013, 26, 973-981.	1.6	36
129	The influence of renal transplantation on retained microbial–human co-metabolites. Nephrology Dialysis Transplantation, 2016, 31, 1721-1729.	0.7	35
130	Uremia Suppresses Immune Signal-Induced CYP27B1 Expression in Human Monocytes. American Journal of Nephrology, 2012, 36, 497-508.	3.1	34
131	Serum Concentrations of <i>p</i> -Cresyl Sulfate and Indoxyl Sulfate, But Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function. Peritoneal Dialysis International, 2014, 34, 71-78.	2.3	34
132	Biomarkers Predicting Bone Turnover in the Setting of CKD. Current Osteoporosis Reports, 2017, 15, 178-186.	3.6	34
133	<i>AQP1</i> Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis. New England Journal of Medicine, 2021, 385, 1570-1580.	27.0	34
134	Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporosis International, 2016, 27, 489-497.	3.1	33
135	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. Nephrology Dialysis Transplantation, 2016, 31, 1508-1514.	0.7	32
136	Update on the role of bone biopsy in the management of patients with CKD–MBD. Journal of Nephrology, 2017, 30, 645-652.	2.0	31
137	Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. American Journal of Kidney Diseases, 2005, 45, e33-e37.	1.9	30
138	Oxidative Stress in Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-2.	4.0	30
139	Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 413-425.	0.7	30
140	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. British Journal of Dermatology, 2007, 158, 071018053044006-???.	1.5	29
141	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. Journal of Antimicrobial Chemotherapy, 2008, 63, 417-419.	3.0	29
142	Simultaneous Control of PTH and Ca×P Is Sustained over Three Years of Treatment with Cinacalcet HCl. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1465-1476.	4.5	29
143	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
144	Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study. , 2021, 31, 512-522.		29

#	Article	IF	CITATIONS
145	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. Drug Metabolism and Disposition, 2004, 32, 1421-1425.	3.3	28
146	Heritability and Clinical Determinants of Serum Indoxyl Sulfate and p-Cresyl Sulfate, Candidate Biomarkers of the Human Microbiome Enterotype. PLoS ONE, 2014, 9, e79682.	2.5	28
147	13C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine. Gut, 2000, 46, 52-57.	12.1	27
148	A Prospective, Randomized, Double-Blind Crossover Study on the Use of 5% Citrate Lock versus 10% Citrate Lock in Permanent Hemodialysis Catheters. Blood Purification, 2005, 23, 101-105.	1.8	27
149	Alteration in digestion and absorption of nutrients during profound acid suppression. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2001, 15, 539-551.	2.4	26
150	â€~Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrology Dialysis Transplantation, 2001, 16, 2258-2262.	0.7	25
151	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. American Journal of Kidney Diseases, 2022, 79, 667-676.e1.	1.9	25
152	Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. Transplant International, 2007, 20, 381-385.	1.6	24
153	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2085-2092.	4.5	23
154	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
155	A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney International, 2019, 95, 412-419.	5.2	23
156	The Role of Gut Dysbiosis in the Bone–Vascular Axis in Chronic Kidney Disease. Toxins, 2020, 12, 285.	3.4	23
157	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. American Journal of Nephrology, 2011, 34, 226-232.	3.1	22
158	p -cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxinÂsky. Kidney International, 2017, 92, 1323-1324.	5.2	22
159	Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrology Dialysis Transplantation, 2018, 33, 1404-1410.	0.7	22
160	Validation of a New Test Meal for a Protein Digestion Breath Test in Humans. Journal of Nutrition, 2004, 134, 806-810.	2.9	21
161	Drug Interaction Between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient. Transplantation, 2005, 79, 737.	1.0	21
162	Clinically Relevant Drug Interaction Between Voriconazole and Tacrolimus in a Primary Renal Allograft Recipient. Transplantation, 2006, 81, 1750-1752.	1.0	21

#	Article	IF	CITATIONS
163	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. Kidney International, 2013, 83, 789-791.	5.2	21
164	Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparinâ€Induced Thrombocytopenia: Doseâ€Finding Study and Safety Evaluation. Artificial Organs, 2013, 37, 482-487.	1.9	21
165	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. Transplantation, 2016, 100, 2188-2193.	1.0	21
166	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrology Dialysis Transplantation, 2020, 35, 697-705.	0.7	21
167	Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients. Therapeutic Drug Monitoring, 2003, 25, 447-451.	2.0	20
168	A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study. Nephrology Dialysis Transplantation, 2017, 32, 707-714.	0.7	20
169	Sclerostin deficiency modifies the development of CKD-MBD in mice. Bone, 2018, 107, 115-123.	2.9	20
170	Traditional and Non-traditional Risk Factors for Osteoporosis in CKD. Calcified Tissue International, 2021, 108, 496-511.	3.1	20
171	Prevalence and determinants of anemia in the immediate postkidney transplant period. Transplant International, 2011, 24, 1208-1215.	1.6	19
172	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. American Journal of Transplantation, 2013, 13, 1910-1914.	4.7	19
173	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrology Dialysis Transplantation, 2021, 36, 160-169.	0.7	19
174	role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplantation Proceedings, 2002, 34, 1164-1170.	0.6	18
175	Heparin-coated dialyzer membranes: is non-inferiority good enough?. Kidney International, 2014, 86, 1084-1086.	5.2	18
176	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
177	1β,25-Dihydroxyvitamin D 3 : A new vitamin D metabolite in human serum. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173, 341-348.	2.5	18
178	Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporosis International, 2021, 32, 2397-2405.	3.1	18
179	Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 855-865.	7.3	18
180	Evidence in Favor of a Severely Impaired Net Intestinal Calcium Absorption in Patients with (Early-Stage) Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 434-441.	3.1	17

#	Article	IF	CITATIONS
181	Microscopic nephrocalcinosis in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2015, 30, 843-848.	0.7	17
182	A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs, 2001, 24, 208-11.	1.4	17
183	In vivo evaluation of a colonic delivery system using isotope techniques. Alimentary Pharmacology and Therapeutics, 2005, 21, 187-194.	3.7	16
184	Daytime Rhythm and Treatment-Related Fluctuations of Serum Phosphorus Concentration in Dialysis Patients. American Journal of Nephrology, 2012, 35, 242-248.	3.1	16
185	Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4210-4217.	3.6	15
186	Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease. Journal of Clinical Medicine, 2019, 8, 2027.	2.4	15
187	Vitamin K in CKD Bone Disorders. Calcified Tissue International, 2021, 108, 476-485.	3.1	15
188	THE EFFECT OF MYCOPHENOLATE MOFETIL ON HEPATITIS B VIRAL LOAD IN STABLE RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS B. Transplantation, 2001, 72, 1165-1166.	1.0	15
189	Uremic Toxins and Vascular Calcification–Missing the Forest for All the Trees. Toxins, 2020, 12, 624.	3.4	14
190	Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. Bone, 2020, 138, 115460.	2.9	14
191	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug–Bug Interaction?. Toxins, 2020, 12, 351.	3.4	14
192	Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. Journal of Endocrinological Investigation, 2021, 44, 1437-1446.	3.3	14
193	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. PLoS ONE, 2021, 16, e0247623.	2.5	14
194	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. American Journal of Nephrology, 2012, 35, 24-30.	3.1	13
195	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. Kidney International, 2014, 86, 1001-1006.	5.2	13
196	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney International Reports, 2020, 5, 627-631.	0.8	13
197	Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. Discoveries, 2016, 4, e55.	2.3	13
198	Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clinical Transplantation, 2003, 17, 171-176.	1.6	12

#	Article	IF	CITATIONS
199	Control of hyperphosphatemia beyond phosphate. Kidney International, 2007, 71, 376-379.	5.2	12
200	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). CKJ: Clinical Kidney Journal, 2015, 8, 567-571.	2.9	12
201	Facing cinacalcet-induced hypocalcemia: sit back andÂrelax?. Kidney International, 2018, 93, 1275-1277.	5.2	12
202	Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney International Reports, 2019, 4, 987-994.	0.8	12
203	A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy. JBMR Plus, 2020, 4, e10353.	2.7	12
204	Natural History of Bone Disease following Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 638-652.	6.1	12
205	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. Transplantation, 2010, 89, 341-346.	1.0	11
206	Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. Kidney International, 2021, 99, 1173-1178.	5.2	11
207	Patterns of renal osteodystrophy 1 year after kidney transplantation. Nephrology Dialysis Transplantation, 2021, 36, 2130-2139.	0.7	11
208	The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transplantation, 2005, 11, 853-854.	2.4	10
209	Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation. Transplantation Proceedings, 2005, 37, 2840-2842.	0.6	10
210	Quantification of 15N-Nitrate in Urine with Gas Chromatography Combustion Isotope Ratio Mass Spectrometry to Estimate Endogenous NO Production. Analytical Chemistry, 2010, 82, 601-607.	6.5	10
211	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. Nephrology Dialysis Transplantation, 2014, 29, 1965-1972.	0.7	10
212	The Bone after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 795-797.	4.5	10
213	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. CKJ: Clinical Kidney Journal, 2021, 14, 1901-1907.	2.9	10
214	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating Systemâ€Based Liver Dialysis. Artificial Organs, 2012, 36, 29-41.	1.9	9
215	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.7	9
216	Bone biomarkers in de novo renal transplant recipients. Clinica Chimica Acta, 2020, 501, 179-185.	1.1	9

#	Article	IF	CITATIONS
217	A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. Journal of Antimicrobial Chemotherapy, 2005, 55, 391-394.	3.0	8
218	Calcium balance in chronic kidney disease: walking the tightrope. Kidney International, 2012, 81, 1057-1059.	5.2	8
219	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients, 2022, 14, 1742.	4.1	8
220	Bone health in ageing men. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 1173-1208.	5.7	8
221	Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease. Bone, 2022, 162, 116482.	2.9	8
222	Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease. JAMA Internal Medicine, 2016, 176, 867.	5.1	7
223	Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?. Kidney International, 2016, 89, 21-23.	5.2	7
224	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. Bone, 2021, 152, 116066.	2.9	7
225	Death with functioning graft–a preventable cause of graft loss. Annals of Transplantation, 2001, 6, 17-20.	0.9	7
226	Magnesium chloride slows gastric emptying, but does not affect digestive functions. Alimentary Pharmacology and Therapeutics, 2002, 16, 1571-1577.	3.7	6
227	Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. Nephrology Dialysis Transplantation, 2009, 24, 3886-3890.	0.7	6
228	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. Transplantation, 2010, 89, 1296-1297.	1.0	6
229	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
230	Sclerostin─A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. Kidney International Reports, 2017, 2, 481-485.	0.8	6
231	Therapy-Resistant Hypercalcemia in a Patient with Inactivating CYP24A1 Mutation and Recurrent Nephrolithiasis: Beware of Concomitant Hyperparathyroidism. Calcified Tissue International, 2020, 107, 524-528.	3.1	6
232	Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study. European Journal of Endocrinology, 2020, 183, 181-189.	3.7	6
233	Prevalence, progression and implications of breast artery calcification in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 295-302.	2.9	6
234	Hepatic and Vascular Vitamin K Status in Patients with High Cardiovascular Risk. Nutrients, 2021, 13, 3490.	4.1	6

#	Article	IF	CITATIONS
235	Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. Acta Oto-rhino-laryngologica Belgica, 2001, 55, 177-86.	0.0	6
236	Clinical utility of bone turnover markers in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 332-338.	2.0	6
237	Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence. Toxins, 2022, 14, 210.	3.4	5
238	Bone histomorphometry for the diagnosis of renal osteodystrophy: a call for harmonization of reference ranges. Kidney International, 2022, 102, 431-434.	5.2	5
239	Lipid Profile Is Negatively Associated with Uremic Toxins in Patients with Kidney Failure—A Tri-National Cohort. Toxins, 2022, 14, 412.	3.4	5
240	A young patient with unexplained acute hepatorenal dysfunction. Nephrology Dialysis Transplantation, 2003, 18, 1220-1222.	0.7	4
241	Phosphate binder therapy—cracks in the tower of strength?. Nature Reviews Nephrology, 2012, 8, 615-616.	9.6	4
242	Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD?. Kidney International, 2017, 91, 11-13.	5.2	4
243	Clinical evidence of direct bone effects of cinacalcet. Kidney International, 2020, 98, 514-515.	5.2	4
244	Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655 Transplantation, 2001, 72, 1593-1594.	1.0	4
245	13C-breath tests in peritoneal dialysis patients. European Journal of Gastroenterology and Hepatology, 2003, 15, 931-932.	1.6	3
246	Coagulation and Fractionated Plasma Separation and Adsorption. American Journal of Transplantation, 2009, 9, 242-243.	4.7	3
247	Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient. Transplant International, 2012, 25, e27-e28.	1.6	3
248	Clinical case report: a rare cause of acute kidney failure – tissue is the issue. Acta Clinica Belgica, 2017, 72, 201-204.	1.2	3
249	Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3532-e3533.	3.6	3
250	Determination of Deuterated Phenylalanine and Tyrosine in Egg Protein by GCQ. Journal of High Resolution Chromatography, 1999, 22, 465-468.	1.4	2
251	Effect of MARS and PROMETHEUS on systemic hemodynamics and vasoactive agents in patients with acute on-chronic alcoholic liver failure: the clash of the titans. European Journal of Gastroenterology and Hepatology, 2006, 18, A38.	1.6	2
252	Transplantation - clinical I. Nephrology Dialysis Transplantation, 2012, 27, ii304-ii316.	0.7	2

#	Article	IF	CITATIONS
253	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. Acta Clinica Belgica, 2013, 68, 215-217.	1.2	2
254	The Case   Hypercalcemia in a child with chronic kidney disease. Kidney International, 2016, 90, 233-234.	5.2	2
255	PTH Receptors and Skeletal Resistance to PTH Action. , 2020, , 51-77.		2
256	Contemporary kidney transplantation has a limited impact on bone microarchitecture. Bone Reports, 2022, 16, 101172.	0.4	2
257	Heparin-Coated Hemodialyzers –The Holy Grail for Patients at Risk of Bleeding?. Nephron Clinical Practice, 2004, 97, c1-c2.	2.3	1
258	189 Improvement in systemic hemodynamics after mars is associated with a decrease in vasoactive substances in patients with acute on chronic liver failure (AOCLF): Results of a randomised trial. Journal of Hepatology, 2004, 40, 61-62.	3.7	1
259	Response to â€~Superior dialytic clearance of β2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis'. Kidney International, 2007, 71, 467-468.	5.2	1
260	Targeting hyperphosphatemia: truth or dare. Kidney International, 2010, 77, 256-257.	5.2	1
261	The metabolomics grail: promising although not yet holy. Kidney International, 2015, 87, 864.	5.2	1
262	Mineral metabolism disturbances in kidney donors: smoke, no fire (yet). Kidney International, 2016, 90, 734-736.	5.2	1
263	Variations of sclerostin with other bone biomarkers over a one-year period in hemodialysis patients. Clinica Chimica Acta, 2018, 486, 183-184.	1.1	1
264	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. CKJ: Clinical Kidney Journal, 2020, 13, 906-908.	2.9	1
265	Spot urine versus 24-hour urine collection for estimation of the generation of uremic toxins originating from gut microbial metabolism. Kidney International, 2020, 98, 782-784.	5.2	1
266	FC 076DIAGNOSTIC ACCURACY OF BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
267	FC 124PATTERNS OF RENAL OSTEODYSTROPHY ONE YEAR AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
268	European hemodialysis patient satisfaction with phosphate binders is associated with serum phosphorus levels: the Dialysis Outcomes and Practice Patterns Study (DOPPS). CKJ: Clinical Kidney Journal, 2021, 14, 1886-1893.	2.9	1
269	Study of protein assimilation, using stable isotope techniques. Revista De Medicina De La Universidad De Navarra, 1998, 42, 104-8.	0.0	1
270	Calcium metabolism in the early post-transplant period. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2011, 63, 89-99.	3.9	1

#	Article	IF	CITATIONS
271	Evaluation of the role of gastric digestion in overall protein assimilation by a combined13C-egg white -14C-octanoic acid breath test. European Journal of Nutrition, 1997, 36, 374-374.	4.6	0
272	Dialysis Techniques in the Critic Ally-III Patient. Acta Clinica Belgica, 2000, 55, 237-243.	1.2	0
273	<i>Opinion</i> : When is Vitamin D Contraindicated in Dialysis Patients?. Seminars in Dialysis, 2009, 22, 242-244.	1.3	0
274	Mineral and bone disease - CKD 1-5. Nephrology Dialysis Transplantation, 2012, 27, ii146-ii158.	0.7	0
275	Cardiovascular complications in CKD 5D. Nephrology Dialysis Transplantation, 2012, 27, ii227-ii251.	0.7	0
276	Bone and mineral diseases - 1. Nephrology Dialysis Transplantation, 2012, 27, ii36-ii37.	0.7	0
277	Recipients' Smoking Habits and Death-Censored Renal Allograft Survival. Transplantation, 2012, 94, 24.	1.0	0
278	Safety Issues Related to Fractionated Plasma Separation, Adsorption, and Dialysis. Artificial Organs, 2013, 37, 743-744.	1.9	0
279	The Clinical Features of Trombotic Microangiopathies Post Transplantation Transplantation, 2014, 98, 532.	1.0	0
280	Proteinuria, Histology and Kidney-Allograft Survival Transplantation, 2014, 98, 78-79.	1.0	0
281	Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 577.	1.6	0
282	SuO003INDOXYL SULFATE AND P-CRESYL SULFATE PROMOTE VASCULAR CALCIFICATION BY GLUCOSE MEDIATED ACTIVATION OF INFLAMMATION AND COAGULATION PATHWAYS. Nephrology Dialysis Transplantation, 2018, 33, i617-i617.	0.7	0
283	Reply to: Poor Vitamin K Status in Chronic Kidney Disease: An Indirect Indicator of Hip Fragility. Journal of Bone and Mineral Research, 2019, 34, 1544-1545.	2.8	0
284	P1064HEPARIN-FREE DIALYSIS: A PHASE II PILOT STUDY USING ASYMMETRIC TRIACETATE (ATA) CELLULOSE DIALYZERS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
285	P1388ASSESSING BONE TURNOVER IN CHRONIC KIDNEY DISEASE: SHOULD WE MEASURE NON-OXIDIZED PTH. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
286	MO455LIPID PROFILE AND UREMIC RETENTION SOLUTES IN PATIENTS WITH END-STAGE KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
287	MO568STATIC PARAMETERS OF HISTOMORPHOMETRY FOR THE EVALUATION OF BONE TURNOVER IN RENAL OSTEODYSTROPHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
288	MO524CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0

#	Article	IF	CITATIONS
289	MO792CONTEMPORARY MINERAL AND BONE DISORDER MARKERS AND TREATMENT AMONG HEMODIALYSIS PATIENTS IN THE EUROPEAN DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
290	Gastric emptying in renal failure patients using the 13C-octanoic acid breath test: facts and artifacts. Peritoneal Dialysis International, 2002, 22, 732-3; author reply 734-5.	2.3	0
291	Living donor kidney transplantation: analysis of the first 40 cases performed in UZ Leuven. Acta Chirurgica Belgica, 2008, 108, 39-44.	0.4	0
292	MO587: Chronic Kidney Disease Induces Endotoxin-Related Activation of The Innate Immune System. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0